Blueprint Medicines Co. Forecasted to Earn FY2027 Earnings of $5.34 Per Share (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of Blueprint Medicines in a note issued to investors on Monday, May 6th. Leerink Partnrs analyst A. Berens anticipates that the biotechnology company will earn $5.34 per share for the year. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share.

Other equities research analysts have also recently issued research reports about the company. Barclays increased their price target on Blueprint Medicines from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday. Piper Sandler lifted their price target on Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a report on Thursday, May 2nd. JMP Securities lifted their target price on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock a “market outperform” rating in a research note on Friday. Finally, Stifel Nicolaus increased their price target on shares of Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Blueprint Medicines presently has a consensus rating of “Hold” and an average price target of $100.31.

Blueprint Medicines Stock Down 0.9 %

BPMC stock opened at $106.25 on Tuesday. The company has a market cap of $6.50 billion, a price-to-earnings ratio of -22.09 and a beta of 0.65. The firm has a 50-day moving average of $92.00 and a two-hundred day moving average of $81.38. Blueprint Medicines has a 12 month low of $43.89 and a 12 month high of $110.93. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The company’s quarterly revenue was up 85.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.65) earnings per share.

Insider Activity at Blueprint Medicines

In other news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the transaction, the director now owns 176,050 shares in the company, valued at approximately $15,365,644. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total value of $2,188,371.44. Following the transaction, the director now directly owns 176,050 shares in the company, valued at $15,365,644. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Landsittel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the sale, the chief financial officer now owns 47,286 shares of the company’s stock, valued at approximately $4,965,030. The disclosure for this sale can be found here. Insiders sold 104,123 shares of company stock worth $9,554,679 in the last three months. 3.88% of the stock is owned by company insiders.

Institutional Trading of Blueprint Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the company. Compass Wealth Management LLC purchased a new position in shares of Blueprint Medicines during the fourth quarter worth about $69,000. PNC Financial Services Group Inc. increased its holdings in shares of Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 329 shares during the period. Van ECK Associates Corp raised its stake in shares of Blueprint Medicines by 28.4% during the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 193 shares during the last quarter. Cutler Group LLC CA lifted its holdings in shares of Blueprint Medicines by 1,685.7% during the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 944 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Blueprint Medicines in the 4th quarter valued at $95,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.